Ask AI
ProCE Banner Activity

Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma: Efficacy, Toxicities, and Practical Implementation

Slideset

Downloadable slideset on how currently available bispecific antibodies are being used in relapsed/refractory follicular lymphoma and strategies to mitigate associated toxicities, address real-world implementation barriers, and optimize safety in practice.

Released: February 03, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc. 

Regeneron Pharmaceuticals, Inc

Target Audience

This educational activity is intended for oncologists, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with follicular lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop strategies to incorporate novel bispecific antibodies into treatment of patients with relapsed/refractory follicular lymphoma

  • Overcome challenges and barriers to integrating novel bispecific antibodies in treatment of relapsed/refractory follicular lymphoma

  • Prepare clinical practice to manage adverse events associated with novel bispecific antibodies in order to effectively care for patients who may receive them as they become available